MTOR and prostate cancer: Previous work has also implicated p110β as a positive regulator of AR transactivation in prostate cancer cell lines [44] and PI3K/mTOR signalling has been shown to either positively or negatively modulate AR transactivation both in prostate cancer cell lines and genetic mouse models of prostate cancer [45,46].